FDA clears prime editors for testing in humans

Biotech company Prime Medicine received a regulator’s green light to start testing its next-generation gene editing candidate in humans. On 29 April, the US Food and Drug Administration approved the biotech’s Investigational New Drug application, which gives Prime the go-ahead to test its first product candidate, PM359, in a phase 1/2 clinical trial in pediatric and adult patients with chronic granulomatosis disease (CGD).

CGD is a rare immunodeficiency caused by mutations in genes that affect phagocyte function by compromising nicotinamide adenine dinucleotide phosphate (NADPH) production and the cells’ ability to produce pathogen-killing reactive oxygen species. This renders patients susceptible to severe life-threatening bacterial and fungal infections. Hematopoietic stem cell transplants are the only definitive cure for CGD.

Access options

Access Nature and 54 other Nature Portfolio journals

Get Nature+, our best-value online-access subscription

24,99 € / 30 days

cancel any time

Subscribe to this journal

Receive 12 print issues and online access

209,00 € per year

only 17,42 € per issue

Buy this article

Purchase on Springer LinkInstant access to full article PDF

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

Log in

Learn about institutional subscriptions

Read our FAQs

Contact customer support

About this article

Cite this article

FDA clears prime editors for testing in humans.
Nat Biotechnol 42, 691 (2024). https://doi.org/10.1038/s41587-024-02264-6

Download citation

Published: 17 May 2024

Issue Date: May 2024

DOI: https://doi.org/10.1038/s41587-024-02264-6

>>> Read full article>>>
Copyright for syndicated content belongs to the linked Source : Nature.com – https://www.nature.com/articles/s41587-024-02264-6